##ANALYSISTYPE=SOMATIC_SINGLESAMPLE
##PIPELINE=megSAP 0.2-716-g4b72072e
##GENOME_BUILD=GRCh38
##CREATION_DATE=2021-11-25
##FILTER=indelError=Likely artifact due to indel reads at this position
##FILTER=low_conf_region=Variant marked as 'low_conf_region'.
##FILTER=off-target=Variant marked as 'off-target'.
##FILTER=str10=Less than 10% or more than 90% of variant supporting reads on one strand
##SAMPLE=<ID=DX000001_01,IsTumor=yes,IsFFPE=no>
##DESCRIPTION=filter=Annotations for filtering and ranking variants.
##DESCRIPTION=quality=Quality parameters - variant quality (QUAL), depth (DP), allele frequency (AF), mean mapping quality of alternate allele (MQM), probability of strand bias for alternate bases as phred score (SAP), probability of allele ballance as phred score (ABP)
##DESCRIPTION=gene=Affected gene list (comma-separated).
##DESCRIPTION=variant_type=Variant type.
##DESCRIPTION=coding_and_splicing=Coding and splicing details (Gene, ENST number, type, impact, exon/intron number, HGVS.c, HGVS.p, Pfam domain).
##DESCRIPTION=coding_and_splicing_refseq=Coding and splicing details based on RefSeq (Gene, RefSeq id, type, impact, exon/intron number, HGVS.c, HGVS.p, Pfam domain).
##DESCRIPTION=regulatory=Regulatory consequence details.
##DESCRIPTION=OMIM=OMIM database annotation.
##DESCRIPTION=ClinVar=ClinVar database annotation.
##DESCRIPTION=HGMD=HGMD database annotation.
##DESCRIPTION=RepeatMasker=RepeatMasker annotation.
##DESCRIPTION=dbSNP=Identifier in dbSNP database.
##DESCRIPTION=1000g=Allele frequency in 1000 genomes project.
##DESCRIPTION=gnomAD=Allele frequency in gnomAD project.
##DESCRIPTION=gnomAD_hom_hemi=Homoyzgous counts and hemizygous counts of gnomAD project (genome data).
##DESCRIPTION=gnomAD_sub=Sub-population allele frequenciens (AFR,AMR,EAS,NFE,SAS) in gnomAD project.
##DESCRIPTION=phyloP=phyloP (100way vertebrate) annotation. Deleterious threshold > 1.6.
##DESCRIPTION=Sift=Sift effect prediction and score for each transcript: D=damaging, T=tolerated.
##DESCRIPTION=PolyPhen=PolyPhen (humVar) effect prediction and score for each transcript: D=probably damaging, P=possibly damaging, B=benign.
##DESCRIPTION=CADD=CADD pathogenicity prediction scores (scaled phred-like). Deleterious threshold > 10-20.
##DESCRIPTION=REVEL=REVEL pathogenicity prediction score. Deleterious threshold > 0.5.
##DESCRIPTION=MaxEntScan=MaxEntScan splicing prediction (reference bases score/alternate bases score).
##DESCRIPTION=dbscSNV=dbscSNV splicing prediction (ADA/RF score).
##DESCRIPTION=COSMIC=COSMIC somatic variant database anntotation.
##DESCRIPTION=MMSplice_DeltaLogitPSI=MMsplice delta Logit PSI score: variant's effect on the exon inclusion - positive score shows higher exon inclusion, negative higher exclusion rate. A score greater than 2 or less than -2 can be considered strong.
##DESCRIPTION=MMSplice_pathogenicity=MMsplice pathogenicity score: probability of pathogenic effect of the variant on splicing
##DESCRIPTION=SpliceAI=SpliceAI prediction of splice-site variations. Probability of the variant being splice-altering (range from 0-1). The score is the maximum value of acceptor/donor gain/loss of all effected genes.
##DESCRIPTION=NGSD_som_c=Somatic variant count in the NGSD.
##DESCRIPTION=NGSD_som_p=Project names of project containing this somatic variant in the NGSD.
##DESCRIPTION=NGSD_som_vicc_interpretation=Somatic variant interpretation according VICC standard in the NGSD.
##DESCRIPTION=NGSD_som_vicc_comment=Somatic VICC interpretation comment in the NGSD.
##DESCRIPTION=NGSD_hom=Homozygous variant count in NGSD.
##DESCRIPTION=NGSD_het=Heterozygous variant count in NGSD.
##DESCRIPTION=NGSD_group=Homozygous / heterozygous variant count in NGSD with the same disease group.
##DESCRIPTION=classification=Classification from the NGSD.
##DESCRIPTION=classification_comment=Classification comment from the NGSD.
##DESCRIPTION=validation=Validation information from the NGSD. Validation results of other samples are listed in brackets!
##DESCRIPTION=comment=Variant comments from the NGSD.
##DESCRIPTION=gene_info=Gene information from NGSD (inheritance mode, gnomAD o/e scores).
##DESCRIPTION=CANCERHOTSPOTS_AA_CHANGE=Amino acid change as in original cancerhotspots.org file
##DESCRIPTION=CANCERHOTSPOTS_TOTAL_MUT=Total mutation count in cancerhotspots.org at certain amino acid position.
##DESCRIPTION=CANCERHOTSPOTS_ALT_COUNT=Count of specific amino acid alteration at same position in cancerhotspots.org.
##FILTER=low_conf_region=Low confidence region for small variant calling based on gnomAD AC0/RF filters and IMGAG trio/twin data.
##DESCRIPTION=tumor_af=Mutant allele frequency in tumor (Sample DX000001_01).
##DESCRIPTION=tumor_dp=Tumor Depth (Sample DX000001_01).
##DESCRIPTION=somatic_classification_comment=Somatic classification comment from the NGSD.
##DESCRIPTION=somatic_classification=Somatic classification from the NGSD.
##DESCRIPTION=ncg_oncogene=1:gene is oncogene according NCG6.0, 0:No oncogene according NCG6.0, na: no information available about gene in NCG6.0. Order is the same as in column gene.
##DESCRIPTION=ncg_tsg=1:gene is TSG according NCG6.0, 0:No TSG according NCG6.0, na: no information available about gene in NCG6.0. Order is the same as in column gene.
#chr	start	end	ref	obs	tumor_af	tumor_dp	filter	quality	gene	variant_type	coding_and_splicing	coding_and_splicing_refseq	regulatory	OMIM	ClinVar	HGMD	RepeatMasker	dbSNP	1000g	gnomAD	gnomAD_hom_hemi	gnomAD_sub	phyloP	Sift	PolyPhen	CADD	REVEL	MaxEntScan	dbscSNV	COSMIC	MMSplice_DeltaLogitPSI	MMSplice_pathogenicity	SpliceAI	NGSD_som_c	NGSD_som_p	NGSD_som_vicc_interpretation	NGSD_som_vicc_comment	NGSD_hom	NGSD_het	NGSD_group	classification	classification_comment	somatic_classification	somatic_classification_comment	validation	comment	gene_info	CANCERHOTSPOTS_AA_CHANGE	CANCERHOTSPOTS_TOTAL_MUT	CANCERHOTSPOTS_ALT_COUNT	ncg_oncogene	ncg_tsg
chr7	140749271	140749271	C	G	0.9962	262		QUAL=255	BRAF	intron	BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron17/18:c.2112+16G>C::,BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron16/18:c.1992+16G>C::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron17/19:c.2112+16G>C::,BRAF:ENST00000646891.1:intron_variant:MODIFIER:intron16/17:c.1992+16G>C::	BRAF:NM_001354609.2:intron_variant:MODIFIER:intron16/18:c.1992+16G>C::,BRAF:NM_001374244.1:intron_variant:MODIFIER:intron17/18:c.2112+16G>C::,BRAF:NM_001374258.1:intron_variant:MODIFIER:intron17/19:c.2112+16G>C::,BRAF:NM_001378467.1:intron_variant:MODIFIER:intron16/18:c.2001+16G>C::,BRAF:NM_001378468.1:intron_variant:MODIFIER:intron16/17:c.1992+16G>C::,BRAF:NM_001378469.1:intron_variant:MODIFIER:intron16/17:c.1926+16G>C::,BRAF:NM_001378470.1:intron_variant:MODIFIER:intron15/17:c.1890+16G>C::,BRAF:NM_001378471.1:intron_variant:MODIFIER:intron15/17:c.1881+16G>C::,BRAF:NM_001378472.1:intron_variant:MODIFIER:intron16/18:c.1836+16G>C::,BRAF:NM_001378473.1:intron_variant:MODIFIER:intron16/17:c.1836+16G>C::,BRAF:NM_001378474.1:intron_variant:MODIFIER:intron16/17:c.1992+16G>C::,BRAF:NM_001378475.1:intron_variant:MODIFIER:intron15/17:c.1728+16G>C::,BRAF:NM_004333.6:intron_variant:MODIFIER:intron16/17:c.1992+16G>C::,BRAF:XM_017012559.1:intron_variant:MODIFIER:intron17/18:c.2112+16G>C::,BRAF:XR_001744857.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron17/19:n.2120+16G>C::,BRAF:XR_001744858.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron15/17:n.1954+16G>C::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]	40393 [benign DISEASE=Rasopathy,not specified,not provided];			rs3789806	0.3480	0.2981	10759,.	0.6742,0.0994,0.1857,0.1423,0.3126	0.3130			11.30				COSV56062530	0.1674	0.1329	0	2	SomaticAndTreatment			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)				1	0
chr7	140749350	140749350	T	C	0.9975	398		QUAL=255	BRAF	synonymous	BRAF:ENST00000288602.11:synonymous_variant:LOW:exon17/19:c.2049A>G:p.Gly683=:PF07714 [Protein tyrosine and serine/threonine kinase],BRAF:ENST00000496384.7:synonymous_variant:LOW:exon16/19:c.1929A>G:p.Gly643=:PF07714 [Protein tyrosine and serine/threonine kinase],BRAF:ENST00000644969.2:synonymous_variant:LOW:exon17/20:c.2049A>G:p.Gly683=:PF07714 [Protein tyrosine and serine/threonine kinase],BRAF:ENST00000646891.1:synonymous_variant:LOW:exon16/18:c.1929A>G:p.Gly643=:PF07714 [Protein tyrosine and serine/threonine kinase]	BRAF:NM_001354609.2:synonymous_variant:LOW:exon16/19:c.1929A>G:p.Gly643=:,BRAF:NM_001374244.1:synonymous_variant:LOW:exon17/19:c.2049A>G:p.Gly683=:,BRAF:NM_001374258.1:synonymous_variant:LOW:exon17/20:c.2049A>G:p.Gly683=:,BRAF:NM_001378467.1:synonymous_variant:LOW:exon16/19:c.1938A>G:p.Gly646=:,BRAF:NM_001378468.1:synonymous_variant:LOW:exon16/18:c.1929A>G:p.Gly643=:,BRAF:NM_001378469.1:synonymous_variant:LOW:exon16/18:c.1863A>G:p.Gly621=:,BRAF:NM_001378470.1:synonymous_variant:LOW:exon15/18:c.1827A>G:p.Gly609=:,BRAF:NM_001378471.1:synonymous_variant:LOW:exon15/18:c.1818A>G:p.Gly606=:,BRAF:NM_001378472.1:synonymous_variant:LOW:exon16/19:c.1773A>G:p.Gly591=:,BRAF:NM_001378473.1:synonymous_variant:LOW:exon16/18:c.1773A>G:p.Gly591=:,BRAF:NM_001378474.1:synonymous_variant:LOW:exon16/18:c.1929A>G:p.Gly643=:,BRAF:NM_001378475.1:synonymous_variant:LOW:exon15/18:c.1665A>G:p.Gly555=:,BRAF:NM_004333.6:synonymous_variant:LOW:exon16/18:c.1929A>G:p.Gly643=:,BRAF:XM_017012559.1:synonymous_variant:LOW:exon17/19:c.2049A>G:p.Gly683=:,BRAF:XR_001744857.1:non_coding_transcript_exon_variant:MODIFIER:exon17/20:n.2057A>G::,BRAF:XR_001744858.1:non_coding_transcript_exon_variant:MODIFIER:exon15/18:n.1891A>G::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]	40391 [benign DISEASE=Noonan syndrome 7,LEOPARD syndrome 3,Rasopathy,not specified,none provided,not provided];			rs9648696	0.3510	0.3008	10921,.	0.6805,0.1035,0.1865,0.1447,0.3145	1.5810			10.59				COSV56058907	-0.1811	0.1294	0	2	SomaticAndTreatment			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)				1	0
chr7	140753336	140753336	A	T	0.3566	1646		QUAL=255	BRAF	missense	BRAF:ENST00000288602.11:missense_variant:MODERATE:exon16/19:c.1919T>A:p.Val640Glu:PF07714 [Protein tyrosine and serine/threonine kinase],BRAF:ENST00000496384.7:missense_variant:MODERATE:exon15/19:c.1799T>A:p.Val600Glu:PF07714 [Protein tyrosine and serine/threonine kinase],BRAF:ENST00000644969.2:missense_variant:MODERATE:exon16/20:c.1919T>A:p.Val640Glu:PF07714 [Protein tyrosine and serine/threonine kinase],BRAF:ENST00000646891.1:missense_variant:MODERATE:exon15/18:c.1799T>A:p.Val600Glu:PF07714 [Protein tyrosine and serine/threonine kinase]	BRAF:NM_001354609.2:missense_variant:MODERATE:exon15/19:c.1799T>A:p.Val600Glu:,BRAF:NM_001374244.1:missense_variant:MODERATE:exon16/19:c.1919T>A:p.Val640Glu:,BRAF:NM_001374258.1:missense_variant:MODERATE:exon16/20:c.1919T>A:p.Val640Glu:,BRAF:NM_001378467.1:missense_variant:MODERATE:exon15/19:c.1808T>A:p.Val603Glu:,BRAF:NM_001378468.1:missense_variant:MODERATE:exon15/18:c.1799T>A:p.Val600Glu:,BRAF:NM_001378469.1:missense_variant:MODERATE:exon15/18:c.1733T>A:p.Val578Glu:,BRAF:NM_001378470.1:missense_variant:MODERATE:exon14/18:c.1697T>A:p.Val566Glu:,BRAF:NM_001378471.1:missense_variant:MODERATE:exon14/18:c.1688T>A:p.Val563Glu:,BRAF:NM_001378472.1:missense_variant:MODERATE:exon15/19:c.1643T>A:p.Val548Glu:,BRAF:NM_001378473.1:missense_variant:MODERATE:exon15/18:c.1643T>A:p.Val548Glu:,BRAF:NM_001378474.1:missense_variant:MODERATE:exon15/18:c.1799T>A:p.Val600Glu:,BRAF:NM_001378475.1:missense_variant:MODERATE:exon14/18:c.1535T>A:p.Val512Glu:,BRAF:NM_004333.6:missense_variant:MODERATE:exon15/18:c.1799T>A:p.Val600Glu:,BRAF:XM_017012559.1:missense_variant:MODERATE:exon16/19:c.1919T>A:p.Val640Glu:,BRAF:XR_001744857.1:non_coding_transcript_exon_variant:MODIFIER:exon16/20:n.1927T>A::,BRAF:XR_001744858.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron14/17:n.1823-3918T>A::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]	13961 [pathogenic, drug response, other DISEASE=Cystic epithelial invagination containing papillae lined by columnar epithelium,Trametinib-Dabrafenib Response,Vemurafenib-Cobimetinib Response,Nephroblastoma,Cerebral arteriovenous malformation,Neoplasm,Melanoma,Papillary thyroid carcinoma,Multiple myeloma,Brainstem glioma,Malignant melanoma of skin,Lung adenocarcinoma,Non-small cell lung cancer,Neoplasm of brain,Colonic neoplasm,Neoplasm of ovary,Gastrointestinal stromal tumor,Neoplasm of the large intestine,Carcinoma of colon,Malignant neoplastic disease,Lung carcinoma,Colorectal cancer,Squamous cell carcinoma of the head and neck,Cardio-facio-cutaneous syndrome,Glioblastoma,Papillary renal cell carcinoma, sporadic,Germ cell tumor, nonseminomatous,Astrocytoma, low-grade, somatic,not provided];			rs113488022		0.0001		0.0000,0.0000,0.0000,0.0000,0.0001	9.2360	D(0.00),D(0.00),D(0.00),D(0.00)	D(0.96),D(0.93),D(0.96),D(0.96)	28.60	0.93			COSV56056643,COSV56065204,COSV56080151	0.0854	0.3675	0	94	SomaticAndTreatment	ONCOGENIC		0	0	0 / 0			activating	[activating] aharmes1 03.04.2020			BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)				1	0
chr7	140777136	140777136	G	A	0.4303	165	off-target	QUAL=255	BRAF	intron	BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron13/18:c.1638-48C>T::,BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron12/18:c.1518-48C>T::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron13/19:c.1638-48C>T::,BRAF:ENST00000646891.1:intron_variant:MODIFIER:intron12/17:c.1518-48C>T::	BRAF:NM_001354609.2:intron_variant:MODIFIER:intron12/18:c.1518-48C>T::,BRAF:NM_001374244.1:intron_variant:MODIFIER:intron13/18:c.1638-48C>T::,BRAF:NM_001374258.1:intron_variant:MODIFIER:intron13/19:c.1638-48C>T::,BRAF:NM_001378467.1:intron_variant:MODIFIER:intron12/18:c.1527-48C>T::,BRAF:NM_001378468.1:intron_variant:MODIFIER:intron12/17:c.1518-48C>T::,BRAF:NM_001378469.1:intron_variant:MODIFIER:intron12/17:c.1452-48C>T::,BRAF:NM_001378470.1:intron_variant:MODIFIER:intron11/17:c.1416-48C>T::,BRAF:NM_001378471.1:intron_variant:MODIFIER:intron11/17:c.1407-48C>T::,BRAF:NM_001378472.1:intron_variant:MODIFIER:intron12/18:c.1362-48C>T::,BRAF:NM_001378473.1:intron_variant:MODIFIER:intron12/17:c.1362-48C>T::,BRAF:NM_001378474.1:intron_variant:MODIFIER:intron12/17:c.1518-48C>T::,BRAF:NM_001378475.1:intron_variant:MODIFIER:intron11/17:c.1254-48C>T::,BRAF:NM_004333.6:intron_variant:MODIFIER:intron12/17:c.1518-48C>T::,BRAF:XM_017012559.1:intron_variant:MODIFIER:intron13/18:c.1638-48C>T::,BRAF:XR_001744857.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron13/19:n.1646-48C>T::,BRAF:XR_001744858.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron13/17:n.1646-48C>T::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]	40378 [benign DISEASE=not specified,not provided];			rs62487918	0.0619	0.0703	288,.	0.0203,0.0317,0.0959,0.0718,0.1123	-0.0310			4.27				COSV56078557	0.0084	0.087	0	1	SomaticAndTreatment			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)				1	0
chr7	140782627	140782627	T	C	0.6230	244		QUAL=255	BRAF	intron	BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron11/18:c.1434+394A>G::,BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron10/18:c.1314+394A>G::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron11/19:c.1434+394A>G::,BRAF:ENST00000646891.1:intron_variant:MODIFIER:intron10/17:c.1314+394A>G::	BRAF:NM_001354609.2:intron_variant:MODIFIER:intron10/18:c.1314+394A>G::,BRAF:NM_001374244.1:intron_variant:MODIFIER:intron11/18:c.1434+394A>G::,BRAF:NM_001374258.1:intron_variant:MODIFIER:intron11/19:c.1434+394A>G::,BRAF:NM_001378467.1:intron_variant:MODIFIER:intron10/18:c.1323+394A>G::,BRAF:NM_001378468.1:intron_variant:MODIFIER:intron10/17:c.1314+394A>G::,BRAF:NM_001378469.1:intron_variant:MODIFIER:intron10/17:c.1248+394A>G::,BRAF:NM_001378470.1:intron_variant:MODIFIER:intron9/17:c.1212+394A>G::,BRAF:NM_001378471.1:intron_variant:MODIFIER:intron9/17:c.1203+394A>G::,BRAF:NM_001378472.1:intron_variant:MODIFIER:intron10/18:c.1158+394A>G::,BRAF:NM_001378473.1:intron_variant:MODIFIER:intron10/17:c.1158+394A>G::,BRAF:NM_001378474.1:intron_variant:MODIFIER:intron10/17:c.1314+394A>G::,BRAF:NM_001378475.1:intron_variant:MODIFIER:intron9/17:c.1050+394A>G::,BRAF:NM_004333.6:intron_variant:MODIFIER:intron10/17:c.1314+394A>G::,BRAF:XM_017012559.1:intron_variant:MODIFIER:intron11/18:c.1434+394A>G::,BRAF:XR_001744857.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron11/19:n.1442+394A>G::,BRAF:XR_001744858.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron11/17:n.1442+394A>G::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]			L1PA8 (LINE/L1)	rs1267642	0.1286	0.0976	785,.		-0.1040			2.15				COSV56180912			0	0				n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)				1	0
chr7	140783805	140783805	C	T	0.4780	295		QUAL=255	BRAF	intron	BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron10/18:c.1298-648G>A::,BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron9/18:c.1178-648G>A::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron10/19:c.1298-648G>A::,BRAF:ENST00000646891.1:intron_variant:MODIFIER:intron9/17:c.1178-648G>A::	BRAF:NM_001354609.2:intron_variant:MODIFIER:intron9/18:c.1178-648G>A::,BRAF:NM_001374244.1:intron_variant:MODIFIER:intron10/18:c.1298-648G>A::,BRAF:NM_001374258.1:intron_variant:MODIFIER:intron10/19:c.1298-648G>A::,BRAF:NM_001378467.1:intron_variant:MODIFIER:intron9/18:c.1187-648G>A::,BRAF:NM_001378468.1:intron_variant:MODIFIER:intron9/17:c.1178-648G>A::,BRAF:NM_001378469.1:intron_variant:MODIFIER:intron9/17:c.1178-714G>A::,BRAF:NM_001378470.1:intron_variant:MODIFIER:intron8/17:c.1076-648G>A::,BRAF:NM_001378471.1:intron_variant:MODIFIER:intron8/17:c.1141-722G>A::,BRAF:NM_001378472.1:intron_variant:MODIFIER:intron9/18:c.1022-648G>A::,BRAF:NM_001378473.1:intron_variant:MODIFIER:intron9/17:c.1022-648G>A::,BRAF:NM_001378474.1:intron_variant:MODIFIER:intron9/17:c.1178-648G>A::,BRAF:NM_001378475.1:intron_variant:MODIFIER:intron8/17:c.914-648G>A::,BRAF:NM_004333.6:intron_variant:MODIFIER:intron9/17:c.1178-648G>A::,BRAF:XM_017012559.1:intron_variant:MODIFIER:intron10/18:c.1298-648G>A::,BRAF:XR_001744857.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron10/19:n.1306-648G>A::,BRAF:XR_001744858.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron10/17:n.1306-648G>A::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]				rs1267644	0.1296	0.0991	828,.		-0.0630			1.33				COSV56180947			0	0				n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)				1	0
chr7	140785535	140785535	T	C	0.9985	659		QUAL=255	BRAF	intron	BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron10/18:c.1297+154A>G::,BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron9/18:c.1177+2013A>G::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron10/19:c.1297+154A>G::,BRAF:ENST00000646891.1:intron_variant:MODIFIER:intron9/17:c.1177+2013A>G::	BRAF:NM_001354609.2:intron_variant:MODIFIER:intron9/18:c.1177+2013A>G::,BRAF:NM_001374244.1:intron_variant:MODIFIER:intron10/18:c.1297+154A>G::,BRAF:NM_001374258.1:intron_variant:MODIFIER:intron10/19:c.1297+154A>G::,BRAF:NM_001378467.1:intron_variant:MODIFIER:intron9/18:c.1186+2013A>G::,BRAF:NM_001378468.1:intron_variant:MODIFIER:intron9/17:c.1177+2013A>G::,BRAF:NM_001378469.1:intron_variant:MODIFIER:intron9/17:c.1177+2013A>G::,BRAF:NM_001378470.1:intron_variant:MODIFIER:intron8/17:c.1075+2013A>G::,BRAF:NM_001378471.1:intron_variant:MODIFIER:intron8/17:c.1141-2452A>G::,BRAF:NM_001378472.1:intron_variant:MODIFIER:intron9/18:c.1021+2013A>G::,BRAF:NM_001378473.1:intron_variant:MODIFIER:intron9/17:c.1021+2013A>G::,BRAF:NM_001378474.1:intron_variant:MODIFIER:intron9/17:c.1177+2013A>G::,BRAF:NM_001378475.1:intron_variant:MODIFIER:intron8/17:c.913+2013A>G::,BRAF:NM_004333.6:intron_variant:MODIFIER:intron9/17:c.1177+2013A>G::,BRAF:XM_017012559.1:intron_variant:MODIFIER:intron10/18:c.1297+154A>G::,BRAF:XR_001744857.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron10/19:n.1305+154A>G::,BRAF:XR_001744858.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron10/17:n.1305+154A>G::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]				rs1267645	0.3470	0.2980	10767,.		2.8290			20.40				COSV56111038			0	2	SomaticAndTreatment			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)				1	0
chr7	140785890	140785890	C	T	1.0000	310		QUAL=255	BRAF	intron	BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron9/18:c.1178-82G>A::,BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron9/18:c.1177+1658G>A::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron9/19:c.1178-82G>A::,BRAF:ENST00000646891.1:intron_variant:MODIFIER:intron9/17:c.1177+1658G>A::	BRAF:NM_001354609.2:intron_variant:MODIFIER:intron9/18:c.1177+1658G>A::,BRAF:NM_001374244.1:intron_variant:MODIFIER:intron9/18:c.1178-82G>A::,BRAF:NM_001374258.1:intron_variant:MODIFIER:intron9/19:c.1178-82G>A::,BRAF:NM_001378467.1:intron_variant:MODIFIER:intron9/18:c.1186+1658G>A::,BRAF:NM_001378468.1:intron_variant:MODIFIER:intron9/17:c.1177+1658G>A::,BRAF:NM_001378469.1:intron_variant:MODIFIER:intron9/17:c.1177+1658G>A::,BRAF:NM_001378470.1:intron_variant:MODIFIER:intron8/17:c.1075+1658G>A::,BRAF:NM_001378471.1:intron_variant:MODIFIER:intron8/17:c.1141-2807G>A::,BRAF:NM_001378472.1:intron_variant:MODIFIER:intron9/18:c.1021+1658G>A::,BRAF:NM_001378473.1:intron_variant:MODIFIER:intron9/17:c.1021+1658G>A::,BRAF:NM_001378474.1:intron_variant:MODIFIER:intron9/17:c.1177+1658G>A::,BRAF:NM_001378475.1:intron_variant:MODIFIER:intron8/17:c.913+1658G>A::,BRAF:NM_004333.6:intron_variant:MODIFIER:intron9/17:c.1177+1658G>A::,BRAF:XM_017012559.1:intron_variant:MODIFIER:intron9/18:c.1178-82G>A::,BRAF:XR_001744857.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron9/19:n.1186-82G>A::,BRAF:XR_001744858.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron9/17:n.1186-82G>A::	regulatory_region_variant:enhancer	164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]				rs1267646	0.3470	0.2979	10734,.		1.7770			16.35				COSV56111046			0	2	SomaticAndTreatment			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)				1	0
chr7	140786488	140786488	C	T	1.0000	231		QUAL=255	BRAF	intron	BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron9/18:c.1178-680G>A::,BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron9/18:c.1177+1060G>A::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron9/19:c.1178-680G>A::,BRAF:ENST00000646891.1:intron_variant:MODIFIER:intron9/17:c.1177+1060G>A::	BRAF:NM_001354609.2:intron_variant:MODIFIER:intron9/18:c.1177+1060G>A::,BRAF:NM_001374244.1:intron_variant:MODIFIER:intron9/18:c.1178-680G>A::,BRAF:NM_001374258.1:intron_variant:MODIFIER:intron9/19:c.1178-680G>A::,BRAF:NM_001378467.1:intron_variant:MODIFIER:intron9/18:c.1186+1060G>A::,BRAF:NM_001378468.1:intron_variant:MODIFIER:intron9/17:c.1177+1060G>A::,BRAF:NM_001378469.1:intron_variant:MODIFIER:intron9/17:c.1177+1060G>A::,BRAF:NM_001378470.1:intron_variant:MODIFIER:intron8/17:c.1075+1060G>A::,BRAF:NM_001378471.1:intron_variant:MODIFIER:intron8/17:c.1141-3405G>A::,BRAF:NM_001378472.1:intron_variant:MODIFIER:intron9/18:c.1021+1060G>A::,BRAF:NM_001378473.1:intron_variant:MODIFIER:intron9/17:c.1021+1060G>A::,BRAF:NM_001378474.1:intron_variant:MODIFIER:intron9/17:c.1177+1060G>A::,BRAF:NM_001378475.1:intron_variant:MODIFIER:intron8/17:c.913+1060G>A::,BRAF:NM_004333.6:intron_variant:MODIFIER:intron9/17:c.1177+1060G>A::,BRAF:XM_017012559.1:intron_variant:MODIFIER:intron9/18:c.1178-680G>A::,BRAF:XR_001744857.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron9/19:n.1186-680G>A::,BRAF:XR_001744858.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron9/17:n.1186-680G>A::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]				rs1267647	0.3470	0.2979	10750,.		-3.0470			0.00				COSV56111057			0	2	SomaticAndTreatment			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)				1	0
chr7	140786713	140786713	A	G	0.4048	620		QUAL=255	BRAF	intron	BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron9/18:c.1177+835T>C::,BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron9/18:c.1177+835T>C::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron9/19:c.1177+835T>C::,BRAF:ENST00000646891.1:intron_variant:MODIFIER:intron9/17:c.1177+835T>C::	BRAF:NM_001354609.2:intron_variant:MODIFIER:intron9/18:c.1177+835T>C::,BRAF:NM_001374244.1:intron_variant:MODIFIER:intron9/18:c.1177+835T>C::,BRAF:NM_001374258.1:intron_variant:MODIFIER:intron9/19:c.1177+835T>C::,BRAF:NM_001378467.1:intron_variant:MODIFIER:intron9/18:c.1186+835T>C::,BRAF:NM_001378468.1:intron_variant:MODIFIER:intron9/17:c.1177+835T>C::,BRAF:NM_001378469.1:intron_variant:MODIFIER:intron9/17:c.1177+835T>C::,BRAF:NM_001378470.1:intron_variant:MODIFIER:intron8/17:c.1075+835T>C::,BRAF:NM_001378471.1:intron_variant:MODIFIER:intron8/17:c.1141-3630T>C::,BRAF:NM_001378472.1:intron_variant:MODIFIER:intron9/18:c.1021+835T>C::,BRAF:NM_001378473.1:intron_variant:MODIFIER:intron9/17:c.1021+835T>C::,BRAF:NM_001378474.1:intron_variant:MODIFIER:intron9/17:c.1177+835T>C::,BRAF:NM_001378475.1:intron_variant:MODIFIER:intron8/17:c.913+835T>C::,BRAF:NM_004333.6:intron_variant:MODIFIER:intron9/17:c.1177+835T>C::,BRAF:XM_017012559.1:intron_variant:MODIFIER:intron9/18:c.1177+835T>C::,BRAF:XR_001744857.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron9/19:n.1185+835T>C::,BRAF:XR_001744858.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron9/17:n.1185+835T>C::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]				rs80191287	0.0617	0.0568	286,.		0.2610			6.80				COSV56285380			0	2	SomaticAndTreatment			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)				1	0
chr7	140786943	140786943	T	C	0.3603	358		QUAL=255	BRAF	intron	BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron9/18:c.1177+605A>G::,BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron9/18:c.1177+605A>G::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron9/19:c.1177+605A>G::,BRAF:ENST00000646891.1:intron_variant:MODIFIER:intron9/17:c.1177+605A>G::	BRAF:NM_001354609.2:intron_variant:MODIFIER:intron9/18:c.1177+605A>G::,BRAF:NM_001374244.1:intron_variant:MODIFIER:intron9/18:c.1177+605A>G::,BRAF:NM_001374258.1:intron_variant:MODIFIER:intron9/19:c.1177+605A>G::,BRAF:NM_001378467.1:intron_variant:MODIFIER:intron9/18:c.1186+605A>G::,BRAF:NM_001378468.1:intron_variant:MODIFIER:intron9/17:c.1177+605A>G::,BRAF:NM_001378469.1:intron_variant:MODIFIER:intron9/17:c.1177+605A>G::,BRAF:NM_001378470.1:intron_variant:MODIFIER:intron8/17:c.1075+605A>G::,BRAF:NM_001378471.1:intron_variant:MODIFIER:intron8/17:c.1141-3860A>G::,BRAF:NM_001378472.1:intron_variant:MODIFIER:intron9/18:c.1021+605A>G::,BRAF:NM_001378473.1:intron_variant:MODIFIER:intron9/17:c.1021+605A>G::,BRAF:NM_001378474.1:intron_variant:MODIFIER:intron9/17:c.1177+605A>G::,BRAF:NM_001378475.1:intron_variant:MODIFIER:intron8/17:c.913+605A>G::,BRAF:NM_004333.6:intron_variant:MODIFIER:intron9/17:c.1177+605A>G::,BRAF:XM_017012559.1:intron_variant:MODIFIER:intron9/18:c.1177+605A>G::,BRAF:XR_001744857.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron9/19:n.1185+605A>G::,BRAF:XR_001744858.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron9/17:n.1185+605A>G::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]			5S (rRNA)	rs1270193	0.1288	0.0976	787,.		-0.2320			4.39				COSV56180974			0.04	0				n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)				1	0
chr7	140789219	140789219	-	A	0.4483	29		QUAL=46	BRAF	intron	BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron8/18:c.1141-1636dup::,BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron8/18:c.1141-1636dup::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron8/19:c.1141-1636dup::,BRAF:ENST00000646891.1:intron_variant:MODIFIER:intron8/17:c.1141-1636dup::	BRAF:NM_001354609.2:intron_variant:MODIFIER:intron8/18:c.1141-1636dup::,BRAF:NM_001374244.1:intron_variant:MODIFIER:intron8/18:c.1141-1636dup::,BRAF:NM_001374258.1:intron_variant:MODIFIER:intron8/19:c.1141-1636dup::,BRAF:NM_001378467.1:intron_variant:MODIFIER:intron8/18:c.1150-1636dup::,BRAF:NM_001378468.1:intron_variant:MODIFIER:intron8/17:c.1141-1636dup::,BRAF:NM_001378469.1:intron_variant:MODIFIER:intron8/17:c.1141-1636dup::,BRAF:NM_001378470.1:intron_variant:MODIFIER:intron7/17:c.1039-1636dup::,BRAF:NM_001378471.1:intron_variant:MODIFIER:intron8/17:c.1140+5088dup::,BRAF:NM_001378472.1:intron_variant:MODIFIER:intron8/18:c.985-1636dup::,BRAF:NM_001378473.1:intron_variant:MODIFIER:intron8/17:c.985-1636dup::,BRAF:NM_001378474.1:intron_variant:MODIFIER:intron8/17:c.1141-1636dup::,BRAF:NM_001378475.1:intron_variant:MODIFIER:intron7/17:c.877-1636dup::,BRAF:NM_004333.6:intron_variant:MODIFIER:intron8/17:c.1141-1636dup::,BRAF:XM_017012559.1:intron_variant:MODIFIER:intron8/18:c.1141-1636dup::,BRAF:XR_001744857.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron8/19:n.1149-1636dup::,BRAF:XR_001744858.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron8/17:n.1149-1636dup::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]			AluSg (SINE/Alu)	rs201489839		0.1163	1197,.					0.25							0	2	SomaticAndTreatment			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)				1	0
chr7	140790582	140790582	C	T	1.0000	108		QUAL=255	BRAF	intron	BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron8/18:c.1141-2998G>A::,BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron8/18:c.1141-2998G>A::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron8/19:c.1141-2998G>A::,BRAF:ENST00000646891.1:intron_variant:MODIFIER:intron8/17:c.1141-2998G>A::	BRAF:NM_001354609.2:intron_variant:MODIFIER:intron8/18:c.1141-2998G>A::,BRAF:NM_001374244.1:intron_variant:MODIFIER:intron8/18:c.1141-2998G>A::,BRAF:NM_001374258.1:intron_variant:MODIFIER:intron8/19:c.1141-2998G>A::,BRAF:NM_001378467.1:intron_variant:MODIFIER:intron8/18:c.1150-2998G>A::,BRAF:NM_001378468.1:intron_variant:MODIFIER:intron8/17:c.1141-2998G>A::,BRAF:NM_001378469.1:intron_variant:MODIFIER:intron8/17:c.1141-2998G>A::,BRAF:NM_001378470.1:intron_variant:MODIFIER:intron7/17:c.1039-2998G>A::,BRAF:NM_001378471.1:intron_variant:MODIFIER:intron8/17:c.1140+3726G>A::,BRAF:NM_001378472.1:intron_variant:MODIFIER:intron8/18:c.985-2998G>A::,BRAF:NM_001378473.1:intron_variant:MODIFIER:intron8/17:c.985-2998G>A::,BRAF:NM_001378474.1:intron_variant:MODIFIER:intron8/17:c.1141-2998G>A::,BRAF:NM_001378475.1:intron_variant:MODIFIER:intron7/17:c.877-2998G>A::,BRAF:NM_004333.6:intron_variant:MODIFIER:intron8/17:c.1141-2998G>A::,BRAF:XM_017012559.1:intron_variant:MODIFIER:intron8/18:c.1141-2998G>A::,BRAF:XR_001744857.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron8/19:n.1149-2998G>A::,BRAF:XR_001744858.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron8/17:n.1149-2998G>A::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]				rs1267634	0.3472	0.2978	10736,.		-2.2880			0.05				COSV56111069			0	1	SomaticAndTreatment			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)				1	0
chr7	140791458	140791458	C	T	0.3604	788		QUAL=255	BRAF	intron	BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron8/18:c.1140+2850G>A::,BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron8/18:c.1140+2850G>A::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron8/19:c.1140+2850G>A::,BRAF:ENST00000646891.1:intron_variant:MODIFIER:intron8/17:c.1140+2850G>A::	BRAF:NM_001354609.2:intron_variant:MODIFIER:intron8/18:c.1140+2850G>A::,BRAF:NM_001374244.1:intron_variant:MODIFIER:intron8/18:c.1140+2850G>A::,BRAF:NM_001374258.1:intron_variant:MODIFIER:intron8/19:c.1140+2850G>A::,BRAF:NM_001378467.1:intron_variant:MODIFIER:intron8/18:c.1149+2850G>A::,BRAF:NM_001378468.1:intron_variant:MODIFIER:intron8/17:c.1140+2850G>A::,BRAF:NM_001378469.1:intron_variant:MODIFIER:intron8/17:c.1140+2850G>A::,BRAF:NM_001378470.1:intron_variant:MODIFIER:intron7/17:c.1038+2850G>A::,BRAF:NM_001378471.1:intron_variant:MODIFIER:intron8/17:c.1140+2850G>A::,BRAF:NM_001378472.1:intron_variant:MODIFIER:intron8/18:c.984+2850G>A::,BRAF:NM_001378473.1:intron_variant:MODIFIER:intron8/17:c.984+2850G>A::,BRAF:NM_001378474.1:intron_variant:MODIFIER:intron8/17:c.1140+2850G>A::,BRAF:NM_001378475.1:intron_variant:MODIFIER:intron7/17:c.876+2850G>A::,BRAF:NM_004333.6:intron_variant:MODIFIER:intron8/17:c.1140+2850G>A::,BRAF:XM_017012559.1:intron_variant:MODIFIER:intron8/18:c.1140+2850G>A::,BRAF:XR_001744857.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron8/19:n.1148+2850G>A::,BRAF:XR_001744858.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron8/17:n.1148+2850G>A::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]			L2b (LINE/L2)	rs62487920	0.0613	0.0565	286,.		-0.3700			2.66				COSV56285408			0	1	SomaticAndTreatment			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)				1	0
chr7	140791531	140791531	-	CAATTTACATATGCTCTTTGAG	0.0792	621		QUAL=151	BRAF	intron	BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron8/18:c.1140+2755_1140+2776dup::,BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron8/18:c.1140+2755_1140+2776dup::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron8/19:c.1140+2755_1140+2776dup::,BRAF:ENST00000646891.1:intron_variant:MODIFIER:intron8/17:c.1140+2755_1140+2776dup::	BRAF:NM_001354609.2:intron_variant:MODIFIER:intron8/18:c.1140+2755_1140+2776dup::,BRAF:NM_001374244.1:intron_variant:MODIFIER:intron8/18:c.1140+2755_1140+2776dup::,BRAF:NM_001374258.1:intron_variant:MODIFIER:intron8/19:c.1140+2755_1140+2776dup::,BRAF:NM_001378467.1:intron_variant:MODIFIER:intron8/18:c.1149+2755_1149+2776dup::,BRAF:NM_001378468.1:intron_variant:MODIFIER:intron8/17:c.1140+2755_1140+2776dup::,BRAF:NM_001378469.1:intron_variant:MODIFIER:intron8/17:c.1140+2755_1140+2776dup::,BRAF:NM_001378470.1:intron_variant:MODIFIER:intron7/17:c.1038+2755_1038+2776dup::,BRAF:NM_001378471.1:intron_variant:MODIFIER:intron8/17:c.1140+2755_1140+2776dup::,BRAF:NM_001378472.1:intron_variant:MODIFIER:intron8/18:c.984+2755_984+2776dup::,BRAF:NM_001378473.1:intron_variant:MODIFIER:intron8/17:c.984+2755_984+2776dup::,BRAF:NM_001378474.1:intron_variant:MODIFIER:intron8/17:c.1140+2755_1140+2776dup::,BRAF:NM_001378475.1:intron_variant:MODIFIER:intron7/17:c.876+2755_876+2776dup::,BRAF:NM_004333.6:intron_variant:MODIFIER:intron8/17:c.1140+2755_1140+2776dup::,BRAF:XM_017012559.1:intron_variant:MODIFIER:intron8/18:c.1140+2755_1140+2776dup::,BRAF:XR_001744857.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron8/19:n.1148+2755_1148+2776dup::,BRAF:XR_001744858.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron8/17:n.1148+2755_1148+2776dup::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]			L2b (LINE/L2)	rs145782099		0.0551	274,.					6.47							0	1	SomaticAndTreatment			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)				1	0
chr7	140792239	140792239	T	C	0.4981	777		QUAL=255	BRAF	intron	BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron8/18:c.1140+2069A>G::,BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron8/18:c.1140+2069A>G::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron8/19:c.1140+2069A>G::,BRAF:ENST00000646891.1:intron_variant:MODIFIER:intron8/17:c.1140+2069A>G::	BRAF:NM_001354609.2:intron_variant:MODIFIER:intron8/18:c.1140+2069A>G::,BRAF:NM_001374244.1:intron_variant:MODIFIER:intron8/18:c.1140+2069A>G::,BRAF:NM_001374258.1:intron_variant:MODIFIER:intron8/19:c.1140+2069A>G::,BRAF:NM_001378467.1:intron_variant:MODIFIER:intron8/18:c.1149+2069A>G::,BRAF:NM_001378468.1:intron_variant:MODIFIER:intron8/17:c.1140+2069A>G::,BRAF:NM_001378469.1:intron_variant:MODIFIER:intron8/17:c.1140+2069A>G::,BRAF:NM_001378470.1:intron_variant:MODIFIER:intron7/17:c.1038+2069A>G::,BRAF:NM_001378471.1:intron_variant:MODIFIER:intron8/17:c.1140+2069A>G::,BRAF:NM_001378472.1:intron_variant:MODIFIER:intron8/18:c.984+2069A>G::,BRAF:NM_001378473.1:intron_variant:MODIFIER:intron8/17:c.984+2069A>G::,BRAF:NM_001378474.1:intron_variant:MODIFIER:intron8/17:c.1140+2069A>G::,BRAF:NM_001378475.1:intron_variant:MODIFIER:intron7/17:c.876+2069A>G::,BRAF:NM_004333.6:intron_variant:MODIFIER:intron8/17:c.1140+2069A>G::,BRAF:XM_017012559.1:intron_variant:MODIFIER:intron8/18:c.1140+2069A>G::,BRAF:XR_001744857.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron8/19:n.1148+2069A>G::,BRAF:XR_001744858.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron8/17:n.1148+2069A>G::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]			L2b (LINE/L2)	rs1267636	0.1414	0.1117	1152,.		-2.3910			0.78				COSV56181027			0	0				n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)				1	0
chr7	140792611	140792611	T	C	0.4481	1051		QUAL=255	BRAF	intron	BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron8/18:c.1140+1697A>G::,BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron8/18:c.1140+1697A>G::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron8/19:c.1140+1697A>G::,BRAF:ENST00000646891.1:intron_variant:MODIFIER:intron8/17:c.1140+1697A>G::	BRAF:NM_001354609.2:intron_variant:MODIFIER:intron8/18:c.1140+1697A>G::,BRAF:NM_001374244.1:intron_variant:MODIFIER:intron8/18:c.1140+1697A>G::,BRAF:NM_001374258.1:intron_variant:MODIFIER:intron8/19:c.1140+1697A>G::,BRAF:NM_001378467.1:intron_variant:MODIFIER:intron8/18:c.1149+1697A>G::,BRAF:NM_001378468.1:intron_variant:MODIFIER:intron8/17:c.1140+1697A>G::,BRAF:NM_001378469.1:intron_variant:MODIFIER:intron8/17:c.1140+1697A>G::,BRAF:NM_001378470.1:intron_variant:MODIFIER:intron7/17:c.1038+1697A>G::,BRAF:NM_001378471.1:intron_variant:MODIFIER:intron8/17:c.1140+1697A>G::,BRAF:NM_001378472.1:intron_variant:MODIFIER:intron8/18:c.984+1697A>G::,BRAF:NM_001378473.1:intron_variant:MODIFIER:intron8/17:c.984+1697A>G::,BRAF:NM_001378474.1:intron_variant:MODIFIER:intron8/17:c.1140+1697A>G::,BRAF:NM_001378475.1:intron_variant:MODIFIER:intron7/17:c.876+1697A>G::,BRAF:NM_004333.6:intron_variant:MODIFIER:intron8/17:c.1140+1697A>G::,BRAF:XM_017012559.1:intron_variant:MODIFIER:intron8/18:c.1140+1697A>G::,BRAF:XR_001744857.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron8/19:n.1148+1697A>G::,BRAF:XR_001744858.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron8/17:n.1148+1697A>G::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]			L2b (LINE/L2)	rs62487921	0.0619	0.0567	291,.		0.0220			3.88				COSV56285428			0	2	SomaticAndTreatment			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)				1	0
chr7	140792749	140792749	A	G	0.4504	393		QUAL=255	BRAF	intron	BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron8/18:c.1140+1559T>C::,BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron8/18:c.1140+1559T>C::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron8/19:c.1140+1559T>C::,BRAF:ENST00000646891.1:intron_variant:MODIFIER:intron8/17:c.1140+1559T>C::	BRAF:NM_001354609.2:intron_variant:MODIFIER:intron8/18:c.1140+1559T>C::,BRAF:NM_001374244.1:intron_variant:MODIFIER:intron8/18:c.1140+1559T>C::,BRAF:NM_001374258.1:intron_variant:MODIFIER:intron8/19:c.1140+1559T>C::,BRAF:NM_001378467.1:intron_variant:MODIFIER:intron8/18:c.1149+1559T>C::,BRAF:NM_001378468.1:intron_variant:MODIFIER:intron8/17:c.1140+1559T>C::,BRAF:NM_001378469.1:intron_variant:MODIFIER:intron8/17:c.1140+1559T>C::,BRAF:NM_001378470.1:intron_variant:MODIFIER:intron7/17:c.1038+1559T>C::,BRAF:NM_001378471.1:intron_variant:MODIFIER:intron8/17:c.1140+1559T>C::,BRAF:NM_001378472.1:intron_variant:MODIFIER:intron8/18:c.984+1559T>C::,BRAF:NM_001378473.1:intron_variant:MODIFIER:intron8/17:c.984+1559T>C::,BRAF:NM_001378474.1:intron_variant:MODIFIER:intron8/17:c.1140+1559T>C::,BRAF:NM_001378475.1:intron_variant:MODIFIER:intron7/17:c.876+1559T>C::,BRAF:NM_004333.6:intron_variant:MODIFIER:intron8/17:c.1140+1559T>C::,BRAF:XM_017012559.1:intron_variant:MODIFIER:intron8/18:c.1140+1559T>C::,BRAF:XR_001744857.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron8/19:n.1148+1559T>C::,BRAF:XR_001744858.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron8/17:n.1148+1559T>C::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]			L2b (LINE/L2)	rs1326918928		0.0001	0,.		0.7040			5.73							0	0				0	1	0 / 0							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)				1	0
chr7	140793229	140793229	A	G	0.4379	644		QUAL=255	BRAF	intron	BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron8/18:c.1140+1079T>C::,BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron8/18:c.1140+1079T>C::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron8/19:c.1140+1079T>C::,BRAF:ENST00000646891.1:intron_variant:MODIFIER:intron8/17:c.1140+1079T>C::	BRAF:NM_001354609.2:intron_variant:MODIFIER:intron8/18:c.1140+1079T>C::,BRAF:NM_001374244.1:intron_variant:MODIFIER:intron8/18:c.1140+1079T>C::,BRAF:NM_001374258.1:intron_variant:MODIFIER:intron8/19:c.1140+1079T>C::,BRAF:NM_001378467.1:intron_variant:MODIFIER:intron8/18:c.1149+1079T>C::,BRAF:NM_001378468.1:intron_variant:MODIFIER:intron8/17:c.1140+1079T>C::,BRAF:NM_001378469.1:intron_variant:MODIFIER:intron8/17:c.1140+1079T>C::,BRAF:NM_001378470.1:intron_variant:MODIFIER:intron7/17:c.1038+1079T>C::,BRAF:NM_001378471.1:intron_variant:MODIFIER:intron8/17:c.1140+1079T>C::,BRAF:NM_001378472.1:intron_variant:MODIFIER:intron8/18:c.984+1079T>C::,BRAF:NM_001378473.1:intron_variant:MODIFIER:intron8/17:c.984+1079T>C::,BRAF:NM_001378474.1:intron_variant:MODIFIER:intron8/17:c.1140+1079T>C::,BRAF:NM_001378475.1:intron_variant:MODIFIER:intron7/17:c.876+1079T>C::,BRAF:NM_004333.6:intron_variant:MODIFIER:intron8/17:c.1140+1079T>C::,BRAF:XM_017012559.1:intron_variant:MODIFIER:intron8/18:c.1140+1079T>C::,BRAF:XR_001744857.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron8/19:n.1148+1079T>C::,BRAF:XR_001744858.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron8/17:n.1148+1079T>C::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]				rs57620608	0.0619	0.0567	292,.		0.2470			7.33				COSV56285434			0	1	SomaticAndTreatment			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)				1	0
chr7	140795742	140795742	C	T	0.3611	36		QUAL=44	BRAF	intron	BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron7/18:c.981-1275G>A::,BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron7/18:c.981-1275G>A::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron7/19:c.981-1275G>A::,BRAF:ENST00000646891.1:intron_variant:MODIFIER:intron7/17:c.981-1275G>A::	BRAF:NM_001354609.2:intron_variant:MODIFIER:intron7/18:c.981-1275G>A::,BRAF:NM_001374244.1:intron_variant:MODIFIER:intron7/18:c.981-1275G>A::,BRAF:NM_001374258.1:intron_variant:MODIFIER:intron7/19:c.981-1275G>A::,BRAF:NM_001378467.1:intron_variant:MODIFIER:intron7/18:c.990-1275G>A::,BRAF:NM_001378468.1:intron_variant:MODIFIER:intron7/17:c.981-1275G>A::,BRAF:NM_001378469.1:intron_variant:MODIFIER:intron7/17:c.981-1275G>A::,BRAF:NM_001378470.1:intron_variant:MODIFIER:intron6/17:c.879-1275G>A::,BRAF:NM_001378471.1:intron_variant:MODIFIER:intron7/17:c.981-1275G>A::,BRAF:NM_001378472.1:intron_variant:MODIFIER:intron7/18:c.825-1275G>A::,BRAF:NM_001378473.1:intron_variant:MODIFIER:intron7/17:c.825-1275G>A::,BRAF:NM_001378474.1:intron_variant:MODIFIER:intron7/17:c.981-1275G>A::,BRAF:NM_001378475.1:intron_variant:MODIFIER:intron6/17:c.717-1275G>A::,BRAF:NM_004333.6:intron_variant:MODIFIER:intron7/17:c.981-1275G>A::,BRAF:XM_017012559.1:intron_variant:MODIFIER:intron7/18:c.981-1275G>A::,BRAF:XR_001744857.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron7/19:n.989-1275G>A::,BRAF:XR_001744858.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron7/17:n.989-1275G>A::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]				rs62487923	0.0613	0.0566	289,.		-0.2650			0.41				COSV56285442			0	1	SomaticAndTreatment			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)				1	0
chr7	140795773	140795773	T	C	1.0000	47		QUAL=255	BRAF	intron	BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron7/18:c.981-1306A>G::,BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron7/18:c.981-1306A>G::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron7/19:c.981-1306A>G::,BRAF:ENST00000646891.1:intron_variant:MODIFIER:intron7/17:c.981-1306A>G::	BRAF:NM_001354609.2:intron_variant:MODIFIER:intron7/18:c.981-1306A>G::,BRAF:NM_001374244.1:intron_variant:MODIFIER:intron7/18:c.981-1306A>G::,BRAF:NM_001374258.1:intron_variant:MODIFIER:intron7/19:c.981-1306A>G::,BRAF:NM_001378467.1:intron_variant:MODIFIER:intron7/18:c.990-1306A>G::,BRAF:NM_001378468.1:intron_variant:MODIFIER:intron7/17:c.981-1306A>G::,BRAF:NM_001378469.1:intron_variant:MODIFIER:intron7/17:c.981-1306A>G::,BRAF:NM_001378470.1:intron_variant:MODIFIER:intron6/17:c.879-1306A>G::,BRAF:NM_001378471.1:intron_variant:MODIFIER:intron7/17:c.981-1306A>G::,BRAF:NM_001378472.1:intron_variant:MODIFIER:intron7/18:c.825-1306A>G::,BRAF:NM_001378473.1:intron_variant:MODIFIER:intron7/17:c.825-1306A>G::,BRAF:NM_001378474.1:intron_variant:MODIFIER:intron7/17:c.981-1306A>G::,BRAF:NM_001378475.1:intron_variant:MODIFIER:intron6/17:c.717-1306A>G::,BRAF:NM_004333.6:intron_variant:MODIFIER:intron7/17:c.981-1306A>G::,BRAF:XM_017012559.1:intron_variant:MODIFIER:intron7/18:c.981-1306A>G::,BRAF:XR_001744857.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron7/19:n.989-1306A>G::,BRAF:XR_001744858.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron7/17:n.989-1306A>G::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]				rs1733826		0.9613	70376,.		-1.2190			0.09							0	0				n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)				1	0
chr7	140795783	140795783	A	C	0.5735	68		QUAL=151	BRAF	intron	BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron7/18:c.981-1316T>G::,BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron7/18:c.981-1316T>G::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron7/19:c.981-1316T>G::,BRAF:ENST00000646891.1:intron_variant:MODIFIER:intron7/17:c.981-1316T>G::	BRAF:NM_001354609.2:intron_variant:MODIFIER:intron7/18:c.981-1316T>G::,BRAF:NM_001374244.1:intron_variant:MODIFIER:intron7/18:c.981-1316T>G::,BRAF:NM_001374258.1:intron_variant:MODIFIER:intron7/19:c.981-1316T>G::,BRAF:NM_001378467.1:intron_variant:MODIFIER:intron7/18:c.990-1316T>G::,BRAF:NM_001378468.1:intron_variant:MODIFIER:intron7/17:c.981-1316T>G::,BRAF:NM_001378469.1:intron_variant:MODIFIER:intron7/17:c.981-1316T>G::,BRAF:NM_001378470.1:intron_variant:MODIFIER:intron6/17:c.879-1316T>G::,BRAF:NM_001378471.1:intron_variant:MODIFIER:intron7/17:c.981-1316T>G::,BRAF:NM_001378472.1:intron_variant:MODIFIER:intron7/18:c.825-1316T>G::,BRAF:NM_001378473.1:intron_variant:MODIFIER:intron7/17:c.825-1316T>G::,BRAF:NM_001378474.1:intron_variant:MODIFIER:intron7/17:c.981-1316T>G::,BRAF:NM_001378475.1:intron_variant:MODIFIER:intron6/17:c.717-1316T>G::,BRAF:NM_004333.6:intron_variant:MODIFIER:intron7/17:c.981-1316T>G::,BRAF:XM_017012559.1:intron_variant:MODIFIER:intron7/18:c.981-1316T>G::,BRAF:XR_001744857.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron7/19:n.989-1316T>G::,BRAF:XR_001744858.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron7/17:n.989-1316T>G::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]				rs75486053	0.0351	0.0471	198,.		1.3430			9.80				COSV56285453			0	0				6	168	1 / 31							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)				1	0
chr7	140796763	140796763	T	C	0.5465	666		QUAL=255	BRAF	intron	BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron7/18:c.981-2296A>G::,BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron7/18:c.981-2296A>G::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron7/19:c.981-2296A>G::,BRAF:ENST00000646891.1:intron_variant:MODIFIER:intron7/17:c.981-2296A>G::	BRAF:NM_001354609.2:intron_variant:MODIFIER:intron7/18:c.981-2296A>G::,BRAF:NM_001374244.1:intron_variant:MODIFIER:intron7/18:c.981-2296A>G::,BRAF:NM_001374258.1:intron_variant:MODIFIER:intron7/19:c.981-2296A>G::,BRAF:NM_001378467.1:intron_variant:MODIFIER:intron7/18:c.990-2296A>G::,BRAF:NM_001378468.1:intron_variant:MODIFIER:intron7/17:c.981-2296A>G::,BRAF:NM_001378469.1:intron_variant:MODIFIER:intron7/17:c.981-2296A>G::,BRAF:NM_001378470.1:intron_variant:MODIFIER:intron6/17:c.879-2296A>G::,BRAF:NM_001378471.1:intron_variant:MODIFIER:intron7/17:c.981-2296A>G::,BRAF:NM_001378472.1:intron_variant:MODIFIER:intron7/18:c.825-2296A>G::,BRAF:NM_001378473.1:intron_variant:MODIFIER:intron7/17:c.825-2296A>G::,BRAF:NM_001378474.1:intron_variant:MODIFIER:intron7/17:c.981-2296A>G::,BRAF:NM_001378475.1:intron_variant:MODIFIER:intron6/17:c.717-2296A>G::,BRAF:NM_004333.6:intron_variant:MODIFIER:intron7/17:c.981-2296A>G::,BRAF:XM_017012559.1:intron_variant:MODIFIER:intron7/18:c.981-2296A>G::,BRAF:XR_001744857.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron7/19:n.989-2296A>G::,BRAF:XR_001744858.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron7/17:n.989-2296A>G::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]			MamRep605 (LTR?)	rs1639675	0.1286	0.0975	786,.		-0.6720			0.40				COSV56181035			0	1	SomaticAndTreatment			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)				1	0
chr7	140797786	140797786	A	T	0.5269	484		QUAL=255	BRAF	intron	BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron7/18:c.980+2576T>A::,BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron7/18:c.980+2576T>A::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron7/19:c.980+2576T>A::,BRAF:ENST00000646891.1:intron_variant:MODIFIER:intron7/17:c.980+2576T>A::	BRAF:NM_001354609.2:intron_variant:MODIFIER:intron7/18:c.980+2576T>A::,BRAF:NM_001374244.1:intron_variant:MODIFIER:intron7/18:c.980+2576T>A::,BRAF:NM_001374258.1:intron_variant:MODIFIER:intron7/19:c.980+2576T>A::,BRAF:NM_001378467.1:intron_variant:MODIFIER:intron7/18:c.989+2576T>A::,BRAF:NM_001378468.1:intron_variant:MODIFIER:intron7/17:c.980+2576T>A::,BRAF:NM_001378469.1:intron_variant:MODIFIER:intron7/17:c.980+2576T>A::,BRAF:NM_001378470.1:intron_variant:MODIFIER:intron6/17:c.878+2576T>A::,BRAF:NM_001378471.1:intron_variant:MODIFIER:intron7/17:c.980+2576T>A::,BRAF:NM_001378472.1:intron_variant:MODIFIER:intron7/18:c.824+2576T>A::,BRAF:NM_001378473.1:intron_variant:MODIFIER:intron7/17:c.824+2576T>A::,BRAF:NM_001378474.1:intron_variant:MODIFIER:intron7/17:c.980+2576T>A::,BRAF:NM_001378475.1:intron_variant:MODIFIER:intron6/17:c.716+2576T>A::,BRAF:NM_004333.6:intron_variant:MODIFIER:intron7/17:c.980+2576T>A::,BRAF:XM_017012559.1:intron_variant:MODIFIER:intron7/18:c.980+2576T>A::,BRAF:XR_001744857.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron7/19:n.988+2576T>A::,BRAF:XR_001744858.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron7/17:n.988+2576T>A::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]				rs73491871	0.1410	0.1110	1136,.		-0.0140			8.50				COSV56181043			0.08	1	SomaticAndTreatment			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)				1	0
chr7	140799503	140799503	T	C	0.4146	808		QUAL=255	BRAF	intron	BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron7/18:c.980+859A>G::,BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron7/18:c.980+859A>G::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron7/19:c.980+859A>G::,BRAF:ENST00000646891.1:intron_variant:MODIFIER:intron7/17:c.980+859A>G::	BRAF:NM_001354609.2:intron_variant:MODIFIER:intron7/18:c.980+859A>G::,BRAF:NM_001374244.1:intron_variant:MODIFIER:intron7/18:c.980+859A>G::,BRAF:NM_001374258.1:intron_variant:MODIFIER:intron7/19:c.980+859A>G::,BRAF:NM_001378467.1:intron_variant:MODIFIER:intron7/18:c.989+859A>G::,BRAF:NM_001378468.1:intron_variant:MODIFIER:intron7/17:c.980+859A>G::,BRAF:NM_001378469.1:intron_variant:MODIFIER:intron7/17:c.980+859A>G::,BRAF:NM_001378470.1:intron_variant:MODIFIER:intron6/17:c.878+859A>G::,BRAF:NM_001378471.1:intron_variant:MODIFIER:intron7/17:c.980+859A>G::,BRAF:NM_001378472.1:intron_variant:MODIFIER:intron7/18:c.824+859A>G::,BRAF:NM_001378473.1:intron_variant:MODIFIER:intron7/17:c.824+859A>G::,BRAF:NM_001378474.1:intron_variant:MODIFIER:intron7/17:c.980+859A>G::,BRAF:NM_001378475.1:intron_variant:MODIFIER:intron6/17:c.716+859A>G::,BRAF:NM_004333.6:intron_variant:MODIFIER:intron7/17:c.980+859A>G::,BRAF:XM_017012559.1:intron_variant:MODIFIER:intron7/18:c.980+859A>G::,BRAF:XR_001744857.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron7/19:n.988+859A>G::,BRAF:XR_001744858.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron7/17:n.988+859A>G::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]				rs117763690	0.0144	0.0157	21,.		-0.8290			0.57							0	1	SomaticAndTreatment			1	83	0 / 19							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)				1	0
chr7	140800335	140800335	C	T	0.4253	1059		QUAL=255	BRAF	intron	BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron7/18:c.980+27G>A::,BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron7/18:c.980+27G>A::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron7/19:c.980+27G>A::,BRAF:ENST00000646891.1:intron_variant:MODIFIER:intron7/17:c.980+27G>A::	BRAF:NM_001354609.2:intron_variant:MODIFIER:intron7/18:c.980+27G>A::,BRAF:NM_001374244.1:intron_variant:MODIFIER:intron7/18:c.980+27G>A::,BRAF:NM_001374258.1:intron_variant:MODIFIER:intron7/19:c.980+27G>A::,BRAF:NM_001378467.1:intron_variant:MODIFIER:intron7/18:c.989+27G>A::,BRAF:NM_001378468.1:intron_variant:MODIFIER:intron7/17:c.980+27G>A::,BRAF:NM_001378469.1:intron_variant:MODIFIER:intron7/17:c.980+27G>A::,BRAF:NM_001378470.1:intron_variant:MODIFIER:intron6/17:c.878+27G>A::,BRAF:NM_001378471.1:intron_variant:MODIFIER:intron7/17:c.980+27G>A::,BRAF:NM_001378472.1:intron_variant:MODIFIER:intron7/18:c.824+27G>A::,BRAF:NM_001378473.1:intron_variant:MODIFIER:intron7/17:c.824+27G>A::,BRAF:NM_001378474.1:intron_variant:MODIFIER:intron7/17:c.980+27G>A::,BRAF:NM_001378475.1:intron_variant:MODIFIER:intron6/17:c.716+27G>A::,BRAF:NM_004333.6:intron_variant:MODIFIER:intron7/17:c.980+27G>A::,BRAF:XM_017012559.1:intron_variant:MODIFIER:intron7/18:c.980+27G>A::,BRAF:XR_001744857.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron7/19:n.988+27G>A::,BRAF:XR_001744858.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron7/17:n.988+27G>A::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]	40354 [benign DISEASE=not specified,not provided];			rs41282721	0.0613	0.0700	290,.	0.0194,0.0317,0.0948,0.0717,0.1119	-0.0360			4.09				COSV56078567,COSV56373227	-0.0215	0.5857	0.01	1	SomaticAndTreatment			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)				1	0
chr7	140808137	140808137	A	T	0.4381	210	off-target	QUAL=255	BRAF	intron	BRAF:ENST00000288602.11:intron_variant:MODIFIER:intron4/18:c.609-75T>A::,BRAF:ENST00000496384.7:intron_variant:MODIFIER:intron4/18:c.609-75T>A::,BRAF:ENST00000644969.2:intron_variant:MODIFIER:intron4/19:c.609-75T>A::,BRAF:ENST00000646891.1:intron_variant:MODIFIER:intron4/17:c.609-75T>A::	BRAF:NM_001354609.2:intron_variant:MODIFIER:intron4/18:c.609-75T>A::,BRAF:NM_001374244.1:intron_variant:MODIFIER:intron4/18:c.609-75T>A::,BRAF:NM_001374258.1:intron_variant:MODIFIER:intron4/19:c.609-75T>A::,BRAF:NM_001378467.1:intron_variant:MODIFIER:intron4/18:c.618-75T>A::,BRAF:NM_001378468.1:intron_variant:MODIFIER:intron4/17:c.609-75T>A::,BRAF:NM_001378469.1:intron_variant:MODIFIER:intron4/17:c.609-75T>A::,BRAF:NM_001378470.1:intron_variant:MODIFIER:intron3/17:c.507-75T>A::,BRAF:NM_001378471.1:intron_variant:MODIFIER:intron4/17:c.609-75T>A::,BRAF:NM_001378472.1:intron_variant:MODIFIER:intron4/18:c.453-75T>A::,BRAF:NM_001378473.1:intron_variant:MODIFIER:intron4/17:c.453-75T>A::,BRAF:NM_001378474.1:intron_variant:MODIFIER:intron4/17:c.609-75T>A::,BRAF:NM_001378475.1:intron_variant:MODIFIER:intron3/17:c.345-75T>A::,BRAF:NM_004333.6:intron_variant:MODIFIER:intron4/17:c.609-75T>A::,BRAF:XM_017012559.1:intron_variant:MODIFIER:intron4/18:c.609-75T>A::,BRAF:XR_001744857.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron4/19:n.617-75T>A::,BRAF:XR_001744858.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron4/17:n.617-75T>A::		164757_[GENE=BRAF_PHENOS=Melanoma, malignant, somatic, 155600 (3); LEOPARD syndrome 3, 613707 (3), Autosomal dominant; Cardiofaciocutaneous syndrome, 115150 (3), Autosomal dominant; Adenocarcinoma of lung, somatic, 211980 (3); Noonan syndrome 7, 613706 (3), Autosomal dominant; Colorectal cancer, somatic, 114500 (3); Nonsmall cell lung cancer, somatic, 211980 (3)]	40344 [benign DISEASE=not provided];			rs17695935	0.0617	0.0565	287,.		3.1020			17.94				COSV56078577	0.0822	0.7282	0	2	SomaticAndTreatment			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							BRAF (inh=AD oe_syn=1.02 oe_mis=0.49 oe_lof=0.10)				1	0
